- Pharmaceutical Executive: October 2024
- Volume 44
- Issue 10
Assembly Required: Building Blocks in Biopharma
Highlighting two pieces beyond Pharm Exec's October headliners that draw interesting parallels when it comes to life sciences leadership and building teams and capability internally—whether new businesses or new brands.
The
But this month, among the rest of our coverage field, I wanted to highlight two pieces beyond the headliners that, while distinctly different from the other, draw interesting parallels when it comes to life sciences leadership and building teams and capability internally—whether new businesses or new brands. And, interestingly, the strategies cover two extremes: startups and Big Pharma.
Concerning the latter, guest author Dan Asch, VP of the oncology franchise at Boehringer Ingelheim, in our
“Building organizational readiness to bring new innovations to those living with cancer requires a very different approach than our work that supports much larger populations,” writes Asch. “Because of that, one of the first things we did was gather our cross-functional partners from across the organization in workshops and forums with experts in rare disease to understand how we need to pivot to serve this community.”
In the other
For more context on both, and the parallels involved, please check out the full articles inside. As always, thanks for reading.
Mike Hennessy Jr. is President and CEO of MJH Life Sciences
Articles in this issue
about 1 year ago
Pharmaceutical Executive: October 2024 Issue (PDF)about 1 year ago
Pharma’s Cold Calling: CGT Space at a Critical Crossroadsabout 1 year ago
‘Selling a Vision’: Today’s Playbook for Startupsabout 1 year ago
Rafaat Rahmani: Beating the Oddsabout 1 year ago
AI: A Value Advantage? Maximizing Your Brand Outreachabout 1 year ago
How to Rally a Team Around Building a New Businessabout 1 year ago
Trading Quality for Convenience? The New Tech Balancing Actabout 1 year ago
Amazon Targeting the Transactional in the Pharma MarketNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.